Jennison Associates Portfolio holdings
Jennison Associates, founded in 1969 and headquartered in New York City, is a global investment management firm managing over $194 billion in assets as of late 2024, specializing in active equity and fixed-income strategies. A subsidiary of PGIM, the asset management arm of Prudential Financial, Jennison serves a diverse client base—including institutions, sub-advisory clients, public plans, endowments, and corporations—with a focus on fundamental research, bottom-up portfolio construction, and high-conviction investing. Known for its equity expertise across styles, geographies, and market capitalizations, as well as investment-grade fixed-income offerings, the firm employs seasoned portfolio managers averaging 29 years of industry experience and 16 years with Jennison. With additional offices in Boston and a culture emphasizing intellectual rigor and long-term client outcomes, Jennison has built a reputation for excellence and stability in the investment management industry.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Alibaba
BABA
|
+$821M |
| 2 |
AGN
Allergan plc
AGN
|
+$444M |
| 3 |
Apple
AAPL
|
+$304M |
| 4 |
TWTR
Twitter, Inc.
TWTR
|
+$301M |
| 5 |
Alphabet (Google) Class C
GOOG
|
+$251M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
RTX Corp
RTX
|
+$839M |
| 2 |
Las Vegas Sands
LVS
|
+$405M |
| 3 |
Qualcomm
QCOM
|
+$402M |
| 4 |
Warner Bros
WBD
|
+$400M |
| 5 |
Perrigo
PRGO
|
+$357M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 18.61% |
| 2 | Consumer Discretionary | 14.39% |
| 3 | Communication Services | 12.98% |
| 4 | Technology | 11.5% |
| 5 | Energy | 10.05% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
476
ProQR Therapeutics
PRQR
$243M
| $10.8M | 0.01% |
+630,370
| New | +$10.1M |
|
|
ZU
477
DELISTED
ZULILY INC CLASS A COMMON STOCK
ZU
| $10.8M | 0.01% |
284,934
-72,206
| -20% | -$2.62M |
|
|
TUES
478
DELISTED
Tuesday Morning Corp
TUES
| $10.7M | 0.01% |
+550,134
| New | +$9.81M |
|
479
MPLX
MPLX
$59.3B
| $10.6M | 0.01% |
180,342
-13,493
| -7% | -$827K |
|
480
Insmed
INSM
$21.4B
| $10.4M | 0.01% |
+800,438
| New | +$12.1M |
|
|
AVDL
481
DELISTED
Avadel Pharmaceuticals
AVDL
| $10.2M | 0.01% |
712,283
-107,504
| -13% | -$1.55M |
|
|
WBMD
482
DELISTED
WebMD Health Corp.
WBMD
| $9.95M | 0.01% |
237,971
-104,394
| -30% | -$5.04M |
|
|
DSCI
483
DELISTED
Derma Sciences, Inc. Common Stock (DE)
DSCI
| $9.57M | 0.01% |
1,149,314
+1,374
| +0.1% | +$12.7K |
|
484
Qualys
QLYS
$5.1B
| $9.54M | 0.01% |
358,470
+34,693
| +11% | +$875K |
|
|
ZOES
485
DELISTED
Zoe's Kitchen, Inc.
ZOES
| $9.28M | 0.01% |
+301,711
| New | +$8.92M |
|
|
EGRX
486
DELISTED
Eagle Pharmaceuticals, Inc.
EGRX
| $8.72M | 0.01% |
689,394
+613,558
| +809% | +$7.61M |
|
487
Evercore
EVR
$12.4B
| $8.35M | 0.01% |
177,735
-1,480,645
| -89% | -$76.7M |
|
|
MKTO
488
DELISTED
MARKETO INC COM STK (DE)
MKTO
| $8.29M | 0.01% |
256,600
+2,797
| +1% | +$81.7K |
|
|
FCSC
489
DELISTED
Fibrocell Science Inc.
FCSC
| $8.02M | 0.01% |
184,320
+169
| +0.1% | +$7.91K |
|
490
Larimar Therapeutics
LRMR
$397M
| $7.94M | 0.01% |
+33,680
| New | +$7.63M |
|
491
Teekay
TK
$1.01B
| $7.53M | 0.01% |
113,486
+47,229
| +71% | +$2.77M |
|
|
ISBC
492
DELISTED
Investors Bancorp, Inc.
ISBC
| $7.08M | 0.01% |
699,451
-1,704
| -0.2% | -$18K |
|
|
PLG
493
Platinum Group Metals
PLG
$164M
| $6.99M | 0.01% |
78,517
+4,856
| +7% | +$529K |
|
|
CBAY
494
DELISTED
Cymabay Therapeutics
CBAY
| $6.84M | 0.01% |
+1,000,000
| New | +$6.15M |
|
|
ASPX
495
DELISTED
AUSPEX PHARMACEUTICALS INC COM STK (DE)
ASPX
| $6.55M | 0.01% |
255,313
-19,965
| -7% | -$425K |
|
|
STAY
496
DELISTED
Extended Stay America, Inc. Paired Share Unit
STAY
| $6.07M | 0.01% |
255,591
-415
| -0.2% | -$9.63K |
|
497
Kirby Corp
KEX
$7.01B
| $5.79M | 0.01% |
49,125
-424
| -0.9% | -$50.5K |
|
|
RVNC
498
DELISTED
Revance Therapeutics, Inc.
RVNC
| $5.78M | 0.01% |
299,194
-821,940
| -73% | -$21.4M |
|
499
Bruker
BRKR
$9.57B
| $5.67M | 0.01% |
306,088
-994,213
| -76% | -$21.2M |
|
500
ExxonMobil
XOM
$644B
| $5.56M | 0.01% |
59,126
-1,545
| -3% | -$154K |
|
Similar funds
Jennison Associates's Q3 2014 Portfolio in Review
As of Q3 2014, Jennison Associates held 788 positions worth $108B, down 0.96% from $109B the previous quarter. Its ten largest holdings account for 20% of the portfolio.
Jennison Associates's Q3 2014 filing shows 82 new, 334 increased, 281 reduced and 71 closed positions. Its largest new stake was Alibaba: 9,140,584 shares worth $812M. The largest sale was RTX Corp, an estimated $839M.
By sector, the portfolio is most concentrated in Healthcare at 19% of assets, up from 18% a quarter earlier, followed by Consumer Discretionary and Communication Services.
- Jennison Associates's largest Q3 2014 buy was Alibaba: 9,140,584 shares worth $812M.
- Jennison Associates added most to Allergan plc in Q3 2014, an estimated $444M increase.
- Jennison Associates's biggest Q3 2014 reduction was Las Vegas Sands, cutting an estimated $405M.
- Jennison Associates fully exited RTX Corp in Q3 2014, selling an estimated $839M.
- Jennison Associates's ten largest holdings make up 20% of its $108B portfolio in Q3 2014.
- Jennison Associates opened 82 new positions and closed 71 in Q3 2014.
- Jennison Associates's portfolio value fell 0.96% quarter-over-quarter to $108B.
Based on Jennison Associates's 13F filing for Q3 2014, filed 5 Nov 2014.